News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
305,247 Results
Type
Article (16570)
Company Profile (299)
Press Release (288372)
Multimedia
Podcasts (78)
Webinars (11)
Section
Business (83017)
Career Advice (202)
Deals (13808)
Drug Delivery (42)
Drug Development (61231)
Employer Resources (35)
FDA (6656)
Job Trends (5738)
News (159489)
Policy (11230)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (975)
Accelerated approval (21)
Adcomms (14)
Allergies (102)
Alliances (22541)
ALS (137)
Alzheimer's disease (1142)
Antibody-drug conjugate (ADC) (253)
Approvals (6898)
Artificial intelligence (264)
Autoimmune disease (129)
Automation (9)
Bankruptcy (106)
Best Places to Work (5152)
BIOSECURE Act (6)
Biosimilars (104)
Biotechnology (230)
Bladder cancer (125)
Brain cancer (52)
Breast cancer (401)
Cancer (3507)
Cardiovascular disease (273)
Career advice (183)
Career pathing (8)
CAR-T (228)
CDC (5)
Cell therapy (588)
Cervical cancer (19)
Clinical research (53676)
Collaboration (1197)
Company closure (2)
Compensation (613)
Complete response letters (43)
COVID-19 (1315)
CRISPR (86)
C-suite (564)
Cystic fibrosis (131)
Data (5003)
Denatured (15)
Depression (111)
Diabetes (305)
Diagnostics (1423)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (9)
Drug discovery (190)
Drug pricing (51)
Drug shortages (5)
Duchenne muscular dystrophy (219)
Earnings (33683)
Editorial (25)
Employer branding (4)
Employer resources (32)
Events (54564)
Executive appointments (627)
FDA (8619)
Fibrodysplasia Ossificans Progressiva (5)
Friedreich's ataxia (9)
Frontotemporal dementia (23)
Funding (1015)
Gene editing (185)
Generative AI (21)
Gene therapy (510)
GLP-1 (618)
Government (1298)
Grass and pollen (5)
Guidances (180)
Healthcare (7079)
HIV (31)
Huntington's disease (44)
IgA nephropathy (80)
Immunology and inflammation (207)
Immuno-oncology (41)
Indications (77)
Infectious disease (1451)
Inflammatory bowel disease (168)
Inflation Reduction Act (10)
Influenza (50)
Intellectual property (176)
Interviews (24)
IPO (7641)
IRA (14)
Job creations (904)
Job search strategy (163)
JPM (42)
Kidney cancer (12)
Labor market (23)
Layoffs (264)
Leadership (9)
Legal (1514)
Liver cancer (49)
Longevity (11)
Lung cancer (475)
Lymphoma (291)
Machine learning (24)
Management (10)
Manufacturing (388)
MASH (136)
Medical device (2838)
Medtech (2849)
Mergers & acquisitions (6809)
Metabolic disorders (866)
Multiple sclerosis (120)
NASH (14)
Neurodegenerative disease (250)
Neuropsychiatric disorders (76)
Neuroscience (2166)
Neurotech (1)
NextGen: Class of 2026 (2136)
Non-profit (910)
Now hiring (30)
Obesity (407)
Opinion (132)
Ovarian cancer (151)
Pain (130)
Pancreatic cancer (175)
Parkinson's disease (261)
Partnered (14)
Patents (314)
Patient recruitment (378)
Peanut (53)
People (27083)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (18711)
Phase 2 (24633)
Phase 3 (15898)
Pipeline (3577)
Policy (94)
Postmarket research (1191)
Preclinical (6906)
Press Release (30)
Prostate cancer (165)
Psychedelics (51)
Radiopharmaceuticals (244)
Rare diseases (692)
Real estate (1495)
Recruiting (14)
Regulatory (11093)
Reports (19)
Research institute (1038)
Resumes & cover letters (19)
Rett syndrome (25)
RNA editing (21)
RSV (30)
Schizophrenia (130)
Series A (188)
Series B (140)
Service/supplier (1)
Sickle cell disease (78)
Special edition (18)
Spinal muscular atrophy (129)
Sponsored (20)
Startups (2043)
State (1)
Stomach cancer (6)
Supply chain (34)
Tariffs (19)
The Weekly (62)
Vaccines (479)
Venture capital (71)
Weight loss (236)
Women's health (30)
Worklife (2)
Date
Last 7 days (370)
Last 30 days (1246)
Last 365 days (19370)
2026 (1775)
2025 (19675)
2024 (22135)
2023 (24158)
2022 (28783)
2021 (29834)
2020 (25118)
2019 (17591)
2018 (12924)
2017 (15059)
2016 (12869)
2015 (15442)
2014 (11235)
2013 (8157)
2012 (8265)
2011 (8393)
2010 (8134)
Location
Africa (179)
Alabama (68)
Alaska (2)
Arizona (87)
Arkansas (5)
Asia (19922)
Australia (3499)
California (7511)
Canada (1988)
China (838)
Colorado (265)
Connecticut (285)
Delaware (267)
Europe (43714)
Florida (981)
Georgia (226)
Hawaii (3)
Idaho (18)
Illinois (418)
India (37)
Indiana (204)
Iowa (10)
Japan (254)
Kansas (81)
Kentucky (13)
Louisiana (7)
Maine (11)
Maryland (779)
Massachusetts (5925)
Michigan (115)
Minnesota (261)
Mississippi (3)
Missouri (32)
Montana (17)
Nebraska (6)
Nevada (43)
New Hampshire (23)
New Jersey (1890)
New Mexico (13)
New York (1889)
North Carolina (857)
North Dakota (6)
Northern California (3689)
Ohio (182)
Oklahoma (12)
Oregon (25)
Pennsylvania (1401)
Puerto Rico (10)
Rhode Island (26)
South America (250)
South Carolina (9)
Southern California (2973)
Tennessee (41)
Texas (991)
United States (25126)
Utah (108)
Virginia (151)
Washington D.C. (38)
Washington State (662)
West Virginia (2)
Wisconsin (48)
305,247 Results for "tolerance therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Antag Therapeutics demonstrates compelling potential of its novel GIPR antagonist for obesity, reporting excellent tolerability in Phase 1 and enhanced weight loss in amylin combination study
January 8, 2026
·
5 min read
Press Releases
Pasithea Therapeutics Announces $1 Million Award by ALS Association to Study the Efficacy, Safety, and Tolerability of PAS-004 for Treatment of ALS
November 26, 2025
·
5 min read
Press Releases
Repertoire® Immune Medicines Announces Strategic Collaboration with Lilly to Develop Tolerizing Therapies for Autoimmune Diseases
January 29, 2026
·
2 min read
Press Releases
Tolerance Bio and ZipCode Bio Announce Strategic R&D Collaboration to Advance Targeted Thymus Therapeutics
September 9, 2025
·
3 min read
Press Releases
Memo Therapeutics AG Publishes Phase I Safety, Tolerability, and Pharmacokinetics Study for Neutralizing Antibody Targeting BKPyV Infection in Clinical and Translational Science
August 20, 2025
·
3 min read
Press Releases
NeuroEM Therapeutics(R) Appoints Dr. W. Scott Burgin as Chief Medical Officer
February 1, 2026
·
2 min read
Press Releases
Indication BioScience Reports First Human Evidence That Atorvo+™ May Improve Statin Tolerability
October 1, 2025
·
3 min read
Press Releases
Tolerance Bio’s Implanted iPSC-derived Thymic Organoids Enable In Vivo Positive Selection of Human T cells and Tumor Burden Reduction in Melanoma
October 28, 2025
·
5 min read
Press Releases
Amylyx Pharmaceuticals Announces New Safety and Tolerability Cohort 1 Data of AMX0114 in ALS from First-in-Human LUMINA Trial
December 8, 2025
·
7 min read
Press Releases
Lilly’s selective amylin agonist, eloralintide, demonstrated meaningful weight loss and favorable tolerability in a Phase 2 study of adults with obesity or overweight
November 7, 2025
·
7 min read
1 of 30,525
Next
